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A man, suffering from an advanced
stage of Buruli ulcer disease, is sitting on a
wobbly stool repairing an old fishnet. As
he limps to add the rags of old clothes he
will use later as bandages to a pot of
boiling water, the stained bandage cover-
ing his oozing wound on his leg and foot
becomes apparent. ‘‘What happened? I was
always good in school and worked hard on my
fields. I was successful. But it’s the jealousy!
Someone in the village cursed me with atom
(Buruli ulcer) and now I’m here like this! Since
then, four years ago, I’ve had to give up my studies,
my wife has left me. It was too much, too long.
And now I have to pay for the schooling of my two
children as well as for my treatment. I can not
participate in the work groups anymore because of
my condition, and so I have no one to help me with
my fields which are ruined because of the time I
spent at the hospital, waiting for healing… I do
have a large family but I have to take care of
myself alone now, without their help. But, my life
isn’t over! I’m still young, I’m strong. My life isn’t
over!’’ He is alone. Waiting.
Introduction
The introductory account is taken from
our field notes of an interview with a Buruli
ulcer disease (BUD) sufferer in Central
Cameroon in February of 2006 who, after
seeking numerous treatments, including
specialized BUD biomedical treatment,
finds himself alone, abandoned by family
and friends, and with few prospects. Was it
the stigma associated with a disease that is
locally attributed to witchcraft that caused
this man’s abandonment, or were there
other elementsinvolved that account for his
present situation? At first glance, it might
indeed seem that in this case, stigma struck
again. But did it?
The discussion on stigma is gaining
ground in the literature about neglected
tropical diseases [1,2]. Two neglected dis-
eases, leprosy and syphilis, are among the
first described as ‘‘repulsive’’ [3], and both
can be considered prototypes of stigmatizing
diseases. Aside from leprosy [4–8] and
sexually transmitted diseases [9], stigma has
been associated with hematuria in urinary
schistosomiasis [10], lesions of onchocercal
skin disease [11–14], scabies [15,16], leish-
maniasis [17], and Buruli ulcer [18,19].
Such labeling of some neglected tropical
diseases as ‘‘stigmatizing’’ may indeed
increase political commitment to these
diseases [2], but it also bears some risks.
Research can easily end up confirming
previous assumptions, i.e., that it is the
social stigma associated with the disease
thatleadstosocialisolation,hampersaccess
to care, and reduces treatment adherence.
Although this may be the case, in contexts
with high levels of poverty and poor health
services, other factors, such as high treat-
ment costs, tedious travel to health centers,
and long hospital admittances, must not be
ignored. In fact, the task of social science
research is to scrutinize all possible expla-
nations, without being blinded by the
apparently obvious. Moreover, a narrow
focus on stigma is not only a methodolog-
ical pitfall, but it is also a dangerous way of
taking responsibility for poor health care
attendance away from the political and
economic domains and placing the blame
on ‘‘culture’’.
The aim of this paper is to caution
against an all too euphoric use of ‘‘stigma’’
in neglected tropical diseases research. In
order to prevent losing sight of the variety
of possible explanatory options, we encour-
age the use of a ‘‘falsificationist’’ approach
with systematic hypothesis testing that
incorporates,butisnot restricted to,stigma.
Stigma Kills
As Van Brakel [7] argues in his literature
review on leprosy and stigma, with condi-
tions like leprosy, AIDS, epilepsy, schizo-
phrenia, etc., the stigma may be worse than
the disease itself. Stigma can produce an
often irrational rejection of its victims by
thestigmatizers,and alsobythestigmatized
themselves (self-stigma) and their allies. For
this reason stigmas are often labeled as
‘‘social killers’’ since this rejection can lead
to loss of social networks, loss of work,
difficulty in finding marriage partners,
divorce, loss of reputation, discrimination,
isolation, ostracism, etc. [20–23].
Furthermore, stigma produces and re-
produces social inequalities and structures
of exclusion. According to Sen [24], ‘‘not to
be able to mix with others might directly
impoverish a person’s life, and also, addi-
tionally reduce economic opportunities that
come from social contact. Indeed, quite
often different aspects of capability depri-
vation and social exclusion may go togeth-
er’’ (p. 14). Precisely because stigma nega-
tively affects the economic and social
capital of households—which are key for
dealing with illness—one could assume that
stigma limits access to health care both by
increasingfeelingsof fearand shame aswell
as by reducing people’s capabilities to
successfully obtain appropriate treatment.
Understandably, victims of stigmatizing
diseases may opt not to attend health
centerssincetheir presencemay reveal their
condition, with the consequent exacerba-
tion of disease and suffering that result from
treatment delay [1]. Various studies show
that stigma associated with sexually trans-
mitted diseases directly or indirectly hinders
access to public health clinics, and hence
stigma is an important disincentive to
seeking treatment [25,26]. Similar argu-
ments have been used in HIV/AIDS
research [27],epilepsy[28],and leprosy[4].
Health centers, above all those that
specialize in sexually transmitted diseases
or leprosy, are public spaces, where the
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discloses the stigmatizing condition of the
user. This may explain why many people
prefer attending health centers or hospitals
far away from their residences in order to
remain anonymous—a coping strategy
that has been described by Pearson [29]
and Barrett [8] for leprosy cases. There-
fore, treatment delay can be the perverse
consequence of one of the main strategies
for coping with stigma: the occultation and
masking of stigma [30].
Treatment Delay beyond
Stigma
However, that stigma hampers access to
health care poses in fact a paradox. Why
should one avoid efficacious treatment if
the disease causes not only physical suffer-
ing but also discrimination and additional
pain due to its stigma? Why should stigma
be an obstacle rather than an incentive for
initiating or complying with treatment?
As we have seen in the previous section,
stigma, and fear of diagnosis, can indeed
pose a barrier, particularly when conse-
quences are potentially devastating, such
as loss of work, shame, divorce, or
abandonment. However, one should not
uncritically accept the inhibiting role of
stigma in accessing health and thereby
neglect other relevant factors, such as the
lack of efficacious drugs or the lack of
resources for coping with illness costs.
For example, arguing against the increas-
ing use of stigma as an all-encompassing
explanation in HIV/AIDS behavioral re-
search, Castro and Farmer [31] pointed out
the following: ‘‘Where is the evidence that
stigma is a barrier for access to treatment,
when in 2002 less than 5% of persons
affected by AIDS in poor countries had
access to highly efficacious antiretroviral
therapy?’’ (p. 53). They reiterate: ‘‘What is
the motivation for learning one’s serostatus
when there is no possibility of being treated
for opportunistic infections?’’ (p. 56). If
efficacious treatment was available, would
they not use it if they could afford it?
Castro and Farmer furthermore suggest
that it is not stigma, but the limited
accessibility of efficacious treatment and
cost barriers that are the main factors
explaining people’s attitudes towards diag-
nostic tests, abandonment of therapies, or
non-treatment. They also show that the
implementation of effective therapy for
mothers in the Dominican Republic has
helped diminish patients’ stigmatization. An
AIDS program in rural Haiti also reported
asharpdeclineinAIDS-relatedstigma[31].
Likewise, Pearson [29], in her study on
leprosy in Nepal, concluded that the poor
quality of care at the established leprosy
health centers, rather than the fear of being
locally known as having leprosy, is decisive
for women not to attend the new services.
Similar findings have been reported for
cancer where new treatments and the
increasing likelihood of patients’ survival
have been demystifying the illness [3].
Social Isolation beyond Stigma
One risk of inadequately using the
conceptof‘‘stigma’’inpublichealthconsists
of attributing social isolation or exclusion to
the stigmatizing character of the illness,
without considering other possibilities.
BUD is a neglected tropical disease that is
considered highly stigmatizing [18,19] due
to its visible lesions but also due to the local
attribution of BUD to social transgressions
and witchcraft [19]. In a study we carried
out in Cameroon [32], BUD exhibits all the
signs of being a stigmatizing disease: BUD is
clearly associated with transgressions of
social norms, such as theft and witchcraft,
and many of its sufferers are abandoned at
the hospitals, leading to the patients’
consequent abandonment of free-of-charge
hospital treatment. Undoubtedly, some of
the physical characteristics of BUD (such as
the bad smell of the ulcer or the deforma-
tions of the effected limbs) are unsightly and
have the potential of inspiring feelings of
insecurity, shame, and discomfort to the
patient. And similar to the account above of
the man with BUD who had been finan-
cially, socially, and emotionally drained due
to his illness, many people with BUD find
themselves alone, without prospects, and
waiting for healing. Nonetheless, a detailed
analysisofthe BUDpatientsadmitted inthe
Ayos and Akonolinga Hospitals in Central
Cameroon revealed that isolation had other
roots: the social isolation patients faced was
due to a household coping strategy attempt-
ing to avoid plunging the household into a
spiral of impoverishment [32].
Although at the Ayos and Akonolinga
hospitals treatment is free of charge, the
cost burden of hospitalization for BUD
accounts for 25.2% of households’ yearly
income [32], more than double the 10%
commonly considered catastrophic for the
household economy [33]. Treatment costs
consist of productivity time lost for patients
and caretakers, transportation expenses
and feeding costs, and to a lesser extent
the purchase of soap, bandages, and extra
medicine. Distance of the hospitals from
the communities and the long periods of
time that patients must remain at the
hospital—median treatment time for all
patients treated at both hospitals during
the period 2002–2007 was 157 days
[32]—are the underlying causes for such
a high cost burden of BUD in Central
Cameroon. Additionally, absence in the
community generates an extra economic
burden, as it hinders continued participa-
tion in community social networks such as
work groups and savings clubs.
Understandably, 62.6% of households
ceased providing financial support for
patients and making regular visits to the
hospital. In fact, for patients who were not
isolated, the cost for their households
during the healing process (a median of
J105.9) was 8.6 times higher than for
Learning Points
1. Stigma kills. It kills socially because it excludes affected persons from social life by
reducing social networks and possibilities to find work, marriage partners, etc.
2. Stigma also kills literally, as a result of stigma-related social exclusion and
treatment delay. Stigma may hinder treatment-seeking in two different ways: (1)
through fear or shame to be seen in public places, e.g., health centers; and (2) as
a result of social exclusion, through reducing economic capital necessary to
cope with illness costs.
3. Stigma is a powerful element in determining health behavior and is one reason
for social isolation and exclusion. But be careful: it is not the only one. A narrow
focus on stigma bears the danger of diverting attention away from structural,
economic, and political factors affecting health behavior. Apart from social
inequalities, other factors like direct and indirect costs of the disease and its
treatment can lead to social isolation.
4. Whether or not it is stigma that limits health-seeking behavior or leads to a
delay in treatment or to social isolation, this has important implications for
health interventions. If stigma is relevant, sensitization campaigns are justified. If
stigma is not or of little relevance, other interventions should be prioritized.
5. Social science research in neglected tropical diseases does not need new
fashions, but solid conceptual frameworks of health-seeking behavior or
vulnerability that study all relevant factors.
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Moreover, patients mentioned social iso-
lation as the principal reason for aban-
donment of biomedical treatment [32].
With regard to delay, the difficulty in
initially distinguishing signs and symptoms
of BUD from everyday insect bites or
abscesses, the lack of familiarity with and
accurate diagnosis of BUD at non-special-
ized hospitals, and the overall difficulty in
successfully treating BUD play significant
roles in late stage arrival at specialized BUD
units. However, delay is mainly related to
householdattemptstominimizeoravoidthe
debilitating costs associated with treatment.
Implications for Public Health
In a nutshell, stigma should not be an
uncritical explanation for treatment delay
or abandonment, but a hypothesis that has
to be carefully tested in the field. To do so
correctly is pivotal for designing adequate
public health interventions.
In those cases where the obstacle for
seeking adequate preventive or curative
care is indeed stigma, public health
programs do well in fighting stigma
through sensitization campaigns. The
classical approach is the Information-
Education-Communication (IEC) cam-
paigns that include culturally adapted
messages about illness and its treatment.
In the words of Stienstra [19] in her
recommendation for improving BUD
detection and control, ‘‘educational pro-
grams should be developed, not only
because they could help in the detection
of cases in an earlier stage of the disease,
but because they might also lower stigma’’.
Such campaigns aim at changing attitudes,
both of the society towards the affected
and of the stigmatized themselves.
However, in those cases where stigma
proves not to be a major obstacle, other
strategies are required. Debacker et al.
[18], in their study on BUD in Benin,
proposed the creation of ‘‘regional centers
that allow patients easy access to treatment
with short travel distances and low treat-
ment costs, coupled with educational ses-
sions. This proximity would render the
follow-up of patients easier and be a source
of new information on the disease for the
population’’. Similarly, in our study on
BUD in Cameroon, where social exclusion
is above all a result of households’ coping
strategies to avoid falling into the ‘‘medical
poverty trap’’ [34], the health policy that is
most likely to be successful is to improve
treatment access, e.g., through a strategy of
decentralization of treatment [32].
Besides sensitization campaigns, im-
proving the quality of care and access to
effective biomedical resources should be a
major focus. Castro and Farmer [31]
suggest that good access to treatment helps
foster an environment which, step by step,
is likely to counteract the vicious circle of
illness, stigma, and poverty.
In order to improve our understanding
of stigma and its psychological and
socioeconomic impact on access to care,
it is of paramount importance to situate
stigma in relation to other factors and to
contextualize it in broader conceptual
frameworks, be it in health-seeking behav-
ior, vulnerability, structural violence, or
social exclusion.
Conclusions
Since the 1990s, ‘‘beliefs’’ have dominat-
ed the behavior change literature of inter-
national health projects. Reflecting back,
the ‘‘beliefs’’ boom was rooted in an
exaggerated enthusiasm of identifying
‘‘wrong beliefs’’ as the barrier to access to
health care. Consequently, well-designed
IEC messages were regarded as the key to
correcting people’s behavior. The overem-
phasis of beliefs, situating the access prob-
lem at the level of ‘‘cultural obstacles’’,
entirely disregarded a person’s socioeco-
nomic status and capacity to cope with
health care costs, or structural factors like
health care infrastructure, quality of care,
etc. Fortunately, today, we have moved to a
moreintegrated view,wherecultural factors
areanalyzedtogetherwithsocial,economic,
political, and environmental factors.
Spilling over from HIV/AIDS and
tuberculosis work, stigma bears the danger
of becoming a new ‘‘cultural boom’’ in
neglected tropical diseases if not systemat-
ically analyzed. Caution is required
against overemphasizing stigma as the sole
factor responsible for limited health care
access. As we have shown, various other
factors can lead to reduced health care
and social isolation. Furthermore, im-
proved availability and especially efficacy
of health care resources does not only
favor access to health care, but can also
play a role in reducing stigma [31].
Uncritical attribution of social exclusion
and lack of access to care to stigma might
detract from other fundamental causes.
The example of BUD in Cameroon [32]
has clearly shown that social isolation and
treatment abandonment is strongly linked
to economic constraints of caretakers and
families, rather than to stigma. Therefore,
well-designed awareness campaigns with
the aim of reducing stigma are unlikely to
lead to successful behavior change if they
are not accompanied by the improvement
of people’s capacities to cope with the
economic costs of illness.
Again, the ‘‘stigma pitfall’’ shows inter-
esting parallels to the ‘‘beliefs pitfall’’.
Looking only at beliefs in order to explain
patients’ visits to traditional healers can
easily detract from other, substantially
more important, reasons for not attending
health centers, e.g., possibly unaffordable,
poor quality, or unavailable biomedical
treatment. Hence, looking at access to
health care through an isolated ‘‘stigma’’
lens can decontextualize the problem and
lead to ineffective solutions.
Stigma is a powerful element in deter-
mining the course of a disease and its social
burden [1,2], and merits attention. Never-
theless, while supporting current appeals to
place stigma on researchers’ and imple-
menters’ agendas, we strongly caution
against uncritically using ‘‘stigma’’ as an
all-explaining concept in public health.
With this appeal for caution, we hope to
contribute to stimulating the discussion on
stigma and to encourage careful analyses
including all factors that play a role in
hindering access to health care.
Supporting Information
Alternative Language Abstract S1
Translation of the abstract into Spanish
by Joan Muela Ribera
Found at: doi:10.1371/journal.pntd.
0000445.s001 (0.03 MB DOC)
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